April 14, 2025
MADRID — Cannabidiol (CBD) extract may offer meaningful benefits for children and adolescents with autism spectrum disorder (ASD), improving social responsiveness and reducing disruptive behavior, results […]
April 11, 2025
TOPLINE: In a 52-week trial among adults with treatment-resistant depression, quetiapine augmentation was more effective than lithium augmentation in reducing symptoms, offered greater cost-effectiveness, and showed […]
April 9, 2025
Some neurologists and a consumer watchdog are raising concerns that a direct-to-consumer telehealth platform affiliated with the drug company Eli Lilly — marketed to individuals concerned […]
April 8, 2025
Referrals to NHS Talking Therapies in England have more than doubled over the past decade. However, a high dropout rate concerns clinicians and mental health experts. […]
April 8, 2025
TOPLINE: Twice-weekly administration of low-dose lysergic acid diethylamide (LSD) over 6 weeks was safe in adults with attention-deficit/hyperactivity disorder (ADHD) but was no better than placebo […]
April 8, 2025
TOPLINE: Any exposure to discrimination was linked to significantly higher risk for depression plus anxiety in US adults than no discrimination, a new study showed. Those […]
April 4, 2025
TOPLINE: Remote interventions for alcohol or drug use disorder led to a reduction in relapse rates by 39% and the mean number of days of substance […]
April 4, 2025
Esketamine combined with a serotonin-norepinephrine reuptake inhibitor (SNRI) for treatment-resistant depression (TRD) was linked to significantly lower rates of several adverse outcomes than esketamine plus a […]
April 4, 2025
TOPLINE: Attention-deficit/hyperactivity disorder (ADHD) in adults was associated with a higher risk for criminal behavior, especially in men and those with comorbidities such as alcohol use […]